Xencor's Phase 1 trial of XmAb412 in healthy volunteers is recruiting
Registry record shows the bispecific antibody study started July 13, 2026, and remains in recruitment as of the August 3 update.
Xencor's registry activity this week centers on one early-stage trial for its bispecific antibody candidate.
- Xencor is recruiting for a Phase 1 trial of XmAb412, described as a first-in-human, randomized, double-blind, placebo-controlled, single and multiple-dose escalation trial to evaluate safety, tolerability, and pharmacokinetics of XmAb412 in healthy adult participants1. The study enrolls an estimated 128 participants1 and lists Xencor, Inc. as the lead sponsor. The trial's actual start date is listed as 2026-07-13, with primary completion estimated for 2027-05 and study completion estimated for 2028-03.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.